Health Care·Health Care Equipment·$13.1B
Insulet Corp (PODD) is a healthcare company that specializes in developing and manufacturing insulin delivery systems for people with diabetes. With a market cap of $13 billion, Insulet plays a significant role in the health care equipment industry, particularly as the demand for diabetes management solutions continues to grow.
EPS (Earnings Per Share)
EPS is a key indicator of the company's profitability and will be closely watched by investors this quarter.
Revenue Growth
Investors will be interested in revenue growth to assess the company's market performance and demand for its products.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
75%
Avg EPS Surprise
+17.33%
Avg Stock Reaction
+3.05%
In the last quarter, Insulet reported an EPS of $1.55, surpassing expectations by nearly 5%. The stock reacted positively, gaining nearly 5% the following day.
Management Promises & Guidance
Overall, expectations are mixed as Insulet has a strong history of beating EPS estimates, but uncertainty remains about revenue growth.
Bull Case
If Insulet can demonstrate strong revenue growth alongside its solid EPS performance, it may attract more investor confidence and drive the stock higher.
Bear Case
Conversely, if the company fails to meet revenue expectations or shows signs of market share loss, it could lead to a negative reaction from investors.
EPS (Earnings Per Share)
N/AEPS is a key indicator of the company's profitability and will be closely watched by investors this quarter.
Revenue Growth
N/AInvestors will be interested in revenue growth to assess the company's market performance and demand for its products.
Market Share in Insulin Delivery
N/AUnderstanding changes in market share can provide insights into Insulet's competitive position and growth potential.
The print will turn on these two things.
Q1
What is the expected revenue growth rate for the upcoming quarter?
This figure will be crucial in determining the company's ability to maintain its growth trajectory and market position.
Q2
How is Insulet addressing competition in the insulin delivery market?
Insights into competitive strategies will help investors gauge the company's future prospects and potential challenges.
Why consensus could be wrong
The Street may be underestimating Insulet's ability to capture additional market share due to its innovative product pipeline.
Supporting Evidence
Insulet has consistently beaten EPS estimates, indicating strong operational performance.
The company's recent investments in R&D could lead to significant advancements in product offerings.
Options pricing suggests higher volatility, indicating that traders expect a significant move, which may not align with conservative revenue projections.
Key Risk
If revenue growth exceeds 15%, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter centers around Insulet's ability to sustain growth in a competitive market.
Bull Confirmed If
Revenue growth of 15% or more year-over-year would confirm the bull case.
Bear Confirmed If
Revenue growth below 5% would support the bear case.
Implied Move
±8.56%
Historical Avg
±3.74%
The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility.
Options price an 8.56% move while the stock has averaged only a 3.74% move over the last 8 quarters, indicating a rich setup.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Insulet beats expectations and raises guidance, history suggests the stock could rise by around 3.7% on the following trading day.
In-Line / Cautious
If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.
Miss
If the company misses expectations, history suggests a potential decline of around 1.1% on the next trading day.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026